4,311
Views
97
CrossRef citations to date
0
Altmetric
Editorial

Cancer nanomedicines: oversold or underappreciated?

, &
Pages 1-5 | Received 13 Oct 2016, Accepted 15 Nov 2016, Published online: 28 Nov 2016

References

  • Hare JI, Lammers T, Ashford MB, et al. Challenges and strategies in anti-cancer nanomedicine development: An industry perspective. Adv Drug Deliv Rev. 2016. DOI:10.1016/j.addr.2016.04.025
  • Thomas A, Teicher BA, Hassan R. Antibody-drug conjugates for cancer therapy. Lancet Oncol. 2016;17:e254–62.
  • Kwon IK, Lee SC, Han B, et al. Analysis on the current status of targeted drug delivery to tumors. J Control Release. 2012;164:108–114.
  • Matsumura Y, Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res. 1986;46:6387–6392.
  • Wilhelm S, Tavares AJ, Dai Q, et al. Analysis of nanoparticle delivery to tumours. Nat Rev Mater. 2016;1:16014. DOI:10.1038/natrevmats.2016.14
  • Lammers T, Kiessling F, Ashford M, et al. Cancer nanomedicine: is targeting our target? Nat Rev Mater. 2016. DOI:10.1038/natrevmats.2016.76
  • Song G, Suzuki OT, Santos CM, et al. Gulp1 is associated with the pharmacokinetics of PEGylated liposomal doxorubicin (PLD) in inbred mouse strains. Nanomedicine. 2016;12:2007–2017.
  • Harrington KJ, Mohammadtaghi S, Uster PS, et al. Effective targeting of solid tumors in patients with locally advanced cancers by radiolabeled pegylated liposomes. Clin Cancer Res. 2001;7:243–254.
  • Petersen GH, Alzghari SK, Chee W, et al. Meta-analysis of clinical and preclinical studies comparing the anticancer efficacy of liposomal versus conventional non-liposomal doxorubicin. J Control Release. 2016;232:255–264.
  • Kroon J, Buijs JT, Van Der Horst G, et al. Liposomal delivery of dexamethasone attenuates prostate cancer bone metastatic tumor growth in vivo. Prostate. 2015;75:815–824.
  • Van Der Meel R, Vehmeijer LJ, Kok RJ, et al. Ligand-targeted particulate nanomedicines undergoing clinical evaluation: current status. Adv Drug Deliv Rev. 2013;65:1284–1298.
  • Raemdonck K, De Smedt SC. Lessons in simplicity that should shape the future of drug delivery. Nat Biotechnol. 2015;33:1026–1027.
  • Van Der Meel R, Fens MH, Vader P, et al. Extracellular vesicles as drug delivery systems: lessons from the liposome field. J Control Release. 2014;195:72–85.
  • Tsoi KM, MacParland SA, Ma X-Z, et al. Mechanism of hard-nanomaterial clearance by the liver. Nat Mater. 2016;15:1212–1221.
  • Sur S, Fries AC, Kinzler KW, et al. Remote loading of preencapsulated drugs into stealth liposomes. Proc Natl Acad Sci U S A. 2014;111:2283–2288.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.